Obesity
Conditions
Brief summary
Morbidly obese patients exhibit impaired secretion of satiation hormones which may contribute to the development of obesity. Bariatric surgery is associated with weight loss and dramatic increase in the secretion of satiation hormones, but the underlying mechanism remains unknown. The investigator's goal is therefore to examine patients before and after sleeve gastrectomy and compare findings to lean controls.
Detailed description
Morbidly obese patients exhibit impaired secretion of satiation hormones cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), which may contribute to the development of obesity. Bariatric surgery is associated with weight loss and dramatic increase in the secretion of satiation hormones, but the underlying mechanism remains unknown. A better understanding of mechanisms involved will assist in development of non-invasive therapeutic strategies. The investigator's goal is therefore to examine patients before and after sleeve gastrectomy and compare findings to lean controls. Gastric and intestinal mucosa will be collected by endoscopy from morbidly obese subjects before and 3 months after sleeve gastrectomy. In Addition, lean controls will be examined. Expression of various gut peptides will be assessed by immunohistochemistry and quantitative polymerase chain reaction (PCR).
Interventions
PROCEDUREsleeve gastrectomy
Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
OTHERno intervention
lean control group
Sponsors
University Hospital, Basel, Switzerland
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Morbidly obese patients scheduled for sleeve gastrectomy * BMI \> 35 kg/m2 * Age: \> 18-65 years Lean, healthy controls * BMI \> 18 and \< 28kg/m2 * Age: \>18-40 years
Exclusion criteria
* Bleeding diathesis * Previous surgery on the gastrointestinal tract (appendectomy acceptable)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quantification of the enteroendocrine cell population | within 3 months after surgery | Expression of enteroendocrine cell population possessing chromogranin A, ghrelin, CCK, PYY, GLP-1 and GLP-2 by immunohistochemistry and quantitative PCR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determination of tissue morphology (crypt depth, villus height) | within 3 months after surgery | Morphometric analysis |
Countries
Switzerland
Outcome results
None listed